WHO Issues Alert Over Severe Lack of Weight-Loss Injections
Fewer than one in 10 patients eligible to benefit from GLP-1 drugs including Wegovy have access to them, states the WHO as it releases its initial advice on the drugs.
With over a billion individuals worldwide now obese, it is advocating for broader and more equitable access to this class of drugs.
Based on forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 if no action is taken.
"Our new guidance affirms that obesity is a chronic disease that can be managed with holistic and lifelong support," remarked its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and supply-chain constraints are significant barriers to broad availability to the treatments that can help people shift significant body mass, notes the body.
Skinny Jab Supply Crisis
Despite the present most optimistic case, the supply of GLP-1 therapies would only suffice for about 100 million people – fewer than 10% of eligible patients, according to the WHO.
The guideline urges governments and firms to widen access, by measures including licensing agreements.
Exclusive production rights on a key compound – the primary ingredient of Novo Nordisk's Wegovy – is set to lapse in multiple nations in 2026.
How Obesity Jabs Function
The injections replicate a body's own hormone to slow digestion, reduce hunger and increase the sense of being full so users consume fewer calories.
Individuals commonly start to lose weight within a few weeks of commencing the once-weekly jabs.
Evidence suggests users may regain a significant portion within a year of halting the medication, when their usual hunger resume.
To be overweight or obese raises your chance for experiencing health problems, like diabetes, cardiovascular issues, brain attack, and some malignancies.
Excess weight impacts people in all nations and was linked to millions of fatalities worldwide in 2024, per the health agency.
